S&P 500   3,380.80 (+0.53%)
DOW   27,816.90 (+0.13%)
QQQ   282.25 (+1.59%)
AAPL   116.79 (+0.85%)
MSFT   212.46 (+1.01%)
FB   266.63 (+1.81%)
GOOGL   1,487.90 (+1.52%)
AMZN   3,221.26 (+2.30%)
TSLA   448.16 (+4.46%)
NVDA   544.58 (+0.62%)
BABA   290.05 (-1.34%)
CGC   14.20 (-0.84%)
MU   47.92 (+2.04%)
GE   6.24 (+0.16%)
AMD   84.86 (+3.50%)
T   28.49 (-0.07%)
F   6.75 (+1.35%)
ACB   4.67 (+0.43%)
GILD   63.32 (+0.21%)
NFLX   527.51 (+5.50%)
DIS   123.31 (-0.62%)
BA   167.86 (+1.57%)
BAC   24.10 (+0.04%)
S&P 500   3,380.80 (+0.53%)
DOW   27,816.90 (+0.13%)
QQQ   282.25 (+1.59%)
AAPL   116.79 (+0.85%)
MSFT   212.46 (+1.01%)
FB   266.63 (+1.81%)
GOOGL   1,487.90 (+1.52%)
AMZN   3,221.26 (+2.30%)
TSLA   448.16 (+4.46%)
NVDA   544.58 (+0.62%)
BABA   290.05 (-1.34%)
CGC   14.20 (-0.84%)
MU   47.92 (+2.04%)
GE   6.24 (+0.16%)
AMD   84.86 (+3.50%)
T   28.49 (-0.07%)
F   6.75 (+1.35%)
ACB   4.67 (+0.43%)
GILD   63.32 (+0.21%)
NFLX   527.51 (+5.50%)
DIS   123.31 (-0.62%)
BA   167.86 (+1.57%)
BAC   24.10 (+0.04%)
S&P 500   3,380.80 (+0.53%)
DOW   27,816.90 (+0.13%)
QQQ   282.25 (+1.59%)
AAPL   116.79 (+0.85%)
MSFT   212.46 (+1.01%)
FB   266.63 (+1.81%)
GOOGL   1,487.90 (+1.52%)
AMZN   3,221.26 (+2.30%)
TSLA   448.16 (+4.46%)
NVDA   544.58 (+0.62%)
BABA   290.05 (-1.34%)
CGC   14.20 (-0.84%)
MU   47.92 (+2.04%)
GE   6.24 (+0.16%)
AMD   84.86 (+3.50%)
T   28.49 (-0.07%)
F   6.75 (+1.35%)
ACB   4.67 (+0.43%)
GILD   63.32 (+0.21%)
NFLX   527.51 (+5.50%)
DIS   123.31 (-0.62%)
BA   167.86 (+1.57%)
BAC   24.10 (+0.04%)
S&P 500   3,380.80 (+0.53%)
DOW   27,816.90 (+0.13%)
QQQ   282.25 (+1.59%)
AAPL   116.79 (+0.85%)
MSFT   212.46 (+1.01%)
FB   266.63 (+1.81%)
GOOGL   1,487.90 (+1.52%)
AMZN   3,221.26 (+2.30%)
TSLA   448.16 (+4.46%)
NVDA   544.58 (+0.62%)
BABA   290.05 (-1.34%)
CGC   14.20 (-0.84%)
MU   47.92 (+2.04%)
GE   6.24 (+0.16%)
AMD   84.86 (+3.50%)
T   28.49 (-0.07%)
F   6.75 (+1.35%)
ACB   4.67 (+0.43%)
GILD   63.32 (+0.21%)
NFLX   527.51 (+5.50%)
DIS   123.31 (-0.62%)
BA   167.86 (+1.57%)
BAC   24.10 (+0.04%)
Log in
NASDAQ:CBLI

Cleveland BioLabs Stock Forecast, Price & News

$2.00
+0.03 (+1.52 %)
(As of 10/1/2020 12:00 AM ET)
Add
Compare
Today's Range
$1.95
Now: $2.00
$2.02
50-Day Range
$1.65
MA: $2.13
$2.69
52-Week Range
$0.50
Now: $2.00
$5.00
Volume53,066 shs
Average Volume931,707 shs
Market Capitalization$26.03 million
P/E RatioN/A
Dividend YieldN/A
Beta0.67
Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in radiation mitigation, oncology immunotherapy, and vaccines. The company's product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and an immunotherapy for oncology and other indications. Its development programs include CBLB612, which is in preclinical studies, a synthetic molecule that activates the toll-like heterodimeric receptor 2/6 and stimulated white blood cell generation; and that has completed Phase II for treating myelosuppressive prophylaxis in patients with breast cancer receiving doxorubicin-cyclophosphamide chemotherapy. The company is also developing Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. Cleveland BioLabs, Inc. has strategic partnerships with the Cleveland Clinic and Roswell Park Cancer Institute. The company was founded in 2003 and is headquartered in Buffalo, New York.
Read More
Cleveland BioLabs logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.64 out of 5 stars


Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CBLI
CUSIPN/A
Phone716-849-6810

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.11 million
Book Value$0.09 per share

Profitability

Net Income$-2,650,000.00
Net Margins-246.88%

Miscellaneous

EmployeesN/A
Market Cap$26.03 million
Next Earnings Date11/12/2020 (Estimated)
OptionableNot Optionable
$2.00
+0.03 (+1.52 %)
(As of 10/1/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CBLI News and Ratings via Email

Sign-up to receive the latest news and ratings for CBLI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cleveland BioLabs (NASDAQ:CBLI) Frequently Asked Questions

How has Cleveland BioLabs' stock price been impacted by COVID-19 (Coronavirus)?

Cleveland BioLabs' stock was trading at $3.15 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CBLI shares have decreased by 36.5% and is now trading at $2.00.
View which stocks have been most impacted by COVID-19
.

When is Cleveland BioLabs' next earnings date?

Cleveland BioLabs is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for Cleveland BioLabs
.

How were Cleveland BioLabs' earnings last quarter?

Cleveland BioLabs, Inc. (NASDAQ:CBLI) posted its earnings results on Friday, May, 15th. The biotechnology company reported ($0.05) EPS for the quarter. The biotechnology company earned $0.16 million during the quarter. Cleveland BioLabs had a negative return on equity of 125.63% and a negative net margin of 246.88%.
View Cleveland BioLabs' earnings history
.

Are investors shorting Cleveland BioLabs?

Cleveland BioLabs saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 270,100 shares, an increase of 89.4% from the August 31st total of 142,600 shares. Based on an average trading volume of 1,420,000 shares, the short-interest ratio is presently 0.2 days. Approximately 4.8% of the company's shares are sold short.
View Cleveland BioLabs' Short Interest
.

Who are some of Cleveland BioLabs' key competitors?

What other stocks do shareholders of Cleveland BioLabs own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cleveland BioLabs investors own include Ibio (IBIO), Inovio Pharmaceuticals (INO), Opko Health (OPK), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Novavax (NVAX), Biocept (BIOC) and Co-Diagnostics (CODX).

Who are Cleveland BioLabs' key executives?

Cleveland BioLabs' management team includes the following people:
  • Dr. Yakov N. Kogan M.B.A., Ph.D., MBA, CEO & Interim Principal Financial Officer (Age 46)
  • Dr. Langdon L. Miller, Pres & Chief Medical Officer (Age 65)
  • Dr. Andrei V. Gudkov, Chief Scientific Officer (Age 63)
  • Dr. Ann Lenich Hards Ph.D., Exec. VP of Regulatory Affairs
  • Dr. Andrei Purmal Ph.D., VP of Chemistry

What is Cleveland BioLabs' stock symbol?

Cleveland BioLabs trades on the NASDAQ under the ticker symbol "CBLI."

How do I buy shares of Cleveland BioLabs?

Shares of CBLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cleveland BioLabs' stock price today?

One share of CBLI stock can currently be purchased for approximately $2.00.

How big of a company is Cleveland BioLabs?

Cleveland BioLabs has a market capitalization of $26.03 million and generates $1.11 million in revenue each year.

What is Cleveland BioLabs' official website?

The official website for Cleveland BioLabs is www.cbiolabs.com.

How can I contact Cleveland BioLabs?

Cleveland BioLabs' mailing address is 73 HIGH STREET, BUFFALO NY, 14203. The biotechnology company can be reached via phone at 716-849-6810 or via email at [email protected]

This page was last updated on 10/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.